Development of a robust T cell assay to retrospectively diagnose SARS-CoV-2 infection and T cell cytokine release assay as diagnostic and monitoring assay in Long COVID patients
- Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR)
- Total publications:10 publications
Grant number: COV-LT2-0004
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$521,757.6Funder
Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR)Principal Investigator
N/A
Research Location
United KingdomLead Research Institution
University of CambridgeResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The current COVID-19 pandemic caused by coronavirus (SARS-CoV-2), has already infected close to 150 million people with over 3 million deaths worldwide. Unfortunately, a significant proportion of people continue to experience distressing and life altering symptoms several months after the initial illness. People with persistent symptoms are currently classified as having Long COVID. Diagnosis of Long COVID is hampered especially in the group of non-hospitalised patients as the majority had asymptomatic to mild infection hence less likely to have generated antibodies against coronavirus and antibody tests miss a significant proportion of patients (~30%). We therefore propose to develop a COVID diagnostic assay that is based on detecting the aspect of the body s immune response (T cell response) that is triggered in this case in response to coronavirus and is most likely to be detected several months to years following infection. The diagnostic assay will be used in clinical setting. This research proposal was birthed in consultation with patients suffering from Long COVID since the initial wave. We set up a Long COVID clinic for non-hospitalised patients in May 2020 at Addenbrooke s, to provide better clinical care and enroll patients into the Cambridge COVID NIHR BioResource. The enrolled patients had bloods taken and we have preliminary results that show our study s feasibility and we want to scale this to an assay that will be able to process high volumes of samples with quick turnaround of results. We will continue to enroll patients and follow them up every 3 months for up to 18 months. We will disseminate our research findings to the public and patients via bulletins to GPs, patient information leaflets generated by the Addenbrooke s media and communications department and to the scientific and medical community via local medical grand rounds, publications in high impact scientific journals and departmental meetings.
Publicationslinked via Europe PMC
Last Updated:41 minutes ago
View all publications at Europe PMC